formin binding protein 1 likeGenealiases: C1orf39 · TOCA1
Q-omics provides the consensus-scored FNBP1L profile across patient tissues and cancer cell-line models. FNBP1L expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FNBP1L is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, FNBP1L RNA expression shows 21,259 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, BLCA, and THYM as cancer lineages where FNBP1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FNBP1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FNBP1L survival associations across molecular data types. FNBP1L RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FNBP1L RNA expression–survival associations across cancer types. High FNBP1L expression shows unfavorable associations in LGG, MESO, CESC, LIHC and BLCA, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FNBP1L RNA expression.
This table summarizes FNBP1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FNBP1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FNBP1L shows lower tumor expression in KICH, KIRC and THCA and higher tumor expression in BLCA, LIHC and UCEC. The BLCA box plot shows higher FNBP1L RNA expression in tumor versus normal tissue (log2 FC = +1.155, t-test p < 0.001).
This table shows molecular features associated with FNBP1L in patient tissues and cancer cell lines. In patient samples, FNBP1L shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FNBP1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
